ResearcherThe University of Texas MD Anderson Cancer CenterNo recent work listed
Abdel Nasser Hosein
Matched on ORCID iD 0000-0003-1567-6700; OpenAlex author ID A5068240507. Sources: OpenAlex.
Their work
- Papers
- 6
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 20
2018: 1 paper · 2019: 2 papers · 2020: 1 paper · 2021: none · 2022: 2 papers
Papers 6
- Translational advances in pancreatic ductal adenocarcinoma therapy. Co-author DOI 10.1038/s43018-022-00349-2↗
- Loss of Rnf43 Accelerates Kras-Mediated Neoplasia and Remodels the Tumor Immune Microenvironment in Pancreatic Adenocarcinoma. Co-author DOI 10.1053/j.gastro.2021.12.273↗
- Pancreatic cancer stroma: an update on therapeutic targeting strategies. Co-author DOI 10.1038/s41575-020-0300-1↗
- Cellular heterogeneity during mouse pancreatic ductal adenocarcinoma progression at single-cell resolution. Co-author DOI 10.1172/jci.insight.129212↗
- Targeting TGFβR2-mutant tumors exposes vulnerabilities to stromal TGFβ blockade in pancreatic cancer. Co-author DOI 10.15252/emmm.201910515↗
- Pancreatic Cancer Metabolism: Molecular Mechanisms and Clinical Applications. Co-author DOI 10.1007/s11912-018-0699-5↗
Closest collaborators
The 20 strongest of 20 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Anirban Maitra · 4 shared papers, 2019–2022 · strength 0.63
- Paper Translational advances in pancreatic ductal adenocarcinoma therapy. DOI 10.1038/s43018-022-00349-2↗
- Paper Pancreatic cancer stroma: an update on therapeutic targeting strategies. DOI 10.1038/s41575-020-0300-1↗
- Paper Loss of Rnf43 Accelerates Kras-Mediated Neoplasia and Remodels the Tumor Immune Microenvironment in Pancreatic Adenocar… DOI 10.1053/j.gastro.2021.12.273↗
- Rolf A. Brekken · 3 shared papers, 2019–2020 · strength 0.36
- Paper Pancreatic cancer stroma: an update on therapeutic targeting strategies. DOI 10.1038/s41575-020-0300-1↗
- Paper Cellular heterogeneity during mouse pancreatic ductal adenocarcinoma progression at single-cell resolution. DOI 10.1172/jci.insight.129212↗
- Paper Targeting TGFβR2-mutant tumors exposes vulnerabilities to stromal TGFβ blockade in pancreatic cancer. DOI 10.15252/emmm.201910515↗
- Andrew J. Aguirre · 1 shared paper, 2022 · strength 0.22
- Stephanie K. Dougan · 1 shared paper, 2022 · strength 0.22
- Mohamed Zaid · 2 shared papers, 2019–2022 · strength 0.21
- Muhammad Shaalan Beg · 1 shared paper, 2018 · strength 0.17
- Wenting Du · 2 shared papers, 2019 · strength 0.17
- Huocong Huang · 2 shared papers, 2019 · strength 0.17
- Takashi Okumura · 1 shared paper, 2022 · strength 0.13
- Lotfi Abou‐Elkacem · 1 shared paper, 2022 · strength 0.13
- Jason Roszik · 1 shared paper, 2022 · strength 0.13
- Maria E. Monberg · 1 shared paper, 2022 · strength 0.13
- Paola A. Guerrero · 1 shared paper, 2022 · strength 0.13
- Bidyut Ghosh · 1 shared paper, 2022 · strength 0.13
- Hans C. Clevers · 1 shared paper, 2022 · strength 0.13
- Aatur Dilip Singhi · 1 shared paper, 2022 · strength 0.13
- Moriah M. Hagopian · 1 shared paper, 2019 · strength 0.08
- Noah B. Sorrelle · 1 shared paper, 2019 · strength 0.08
- Yuqing Zhang · 1 shared paper, 2019 · strength 0.08
- Eugene Jon Koay · 1 shared paper, 2019 · strength 0.08
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.